Want to see SE:SYNACT full AI Analyst Report?
Top Page
SynAct Pharma AB
(SYNACT)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr19.00
▲(2.81% Upside)
Action:Reiterated
Date:07/11/26
The score is held down primarily by weak financial performance (no revenue, large ongoing losses, and negative free cash flow), partially offset by a strong technical setup (price above major moving averages and positive MACD). Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Low leverage and sizable equity buffer
The near-zero debt-to-equity and a meaningful equity base (~193.7M TTM) provide durable financial flexibility for an R&D-heavy biotech. This reduces near-term solvency risk, supports runway for clinical programs, and enables funding of trials without immediate pressure from fixed interest obligations.
Negative Factors
Zero revenue and persistent large losses
No top-line revenue and recurring large net losses (TTM ~111.6M) reflect a pre-commercial model dependent entirely on pipeline success and external funding. Over months, this structural absence of revenue increases funding risk, heightens dilution potential, and means shareholder value is contingent on future clinical and regulatory outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and sizable equity buffer
The near-zero debt-to-equity and a meaningful equity base (~193.7M TTM) provide durable financial flexibility for an R&D-heavy biotech. This reduces near-term solvency risk, supports runway for clinical programs, and enables funding of trials without immediate pressure from fixed interest obligations.
Read all positive factors
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr973.81M
Dividend YieldN/A
Average Volume (3M)214.83K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue GrowthN/A
EPS Growth-12.27%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.14
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently ...
How the Company Makes Money
null...
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K |
| EBITDA | -119.07M | -116.52M | -15.40M | -222.70M | -105.71M | -76.62M |
| Net Income | -111.63M | -110.83M | -82.40M | -215.81M | -99.20M | -69.30M |
Balance Sheet | ||||||
| Total Assets | 237.88M | 220.52M | 270.52M | 228.02M | 142.60M | 38.37M |
| Cash, Cash Equivalents and Short-Term Investments | 65.78M | 53.41M | 61.21M | 62.40M | 108.25M | 24.00M |
| Total Debt | 1.07M | 1.81M | 1.88M | 637.00K | 2.06M | 3.09M |
| Total Liabilities | 44.13M | 50.23M | 56.35M | 51.83M | 16.08M | 17.50M |
| Stockholders Equity | 193.75M | 170.29M | 214.17M | 176.19M | 126.52M | 20.87M |
Cash Flow | ||||||
| Free Cash Flow | -82.69M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Operating Cash Flow | -82.69M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K |
| Financing Cash Flow | 80.13M | 90.46M | 87.41M | 53.98M | 200.71M | 74.32M |
SynAct Pharma AB Technical Analysis
Neutral
18.48
Price Trends
16.67
Positive
16.80
Positive
19.04
Negative
Market Momentum
0.72
Positive
51.02
Neutral
9.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Neutral. The current price of 18.48 is below the 20-day moving average (MA) of 19.19, above the 50-day MA of 16.67, and below the 200-day MA of 19.04, indicating a neutral trend. The MACD of 0.72 indicates Positive momentum. The RSI at 51.02 is Neutral, neither overbought nor oversold. The STOCH value of 9.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | kr513.70M | 2.80 | 77.69% | ― | ― | ― | |
62 Neutral | kr1.96B | 8.95 | 38.53% | ― | 26.85% | -18.05% | |
56 Neutral | kr973.81M | -8.53 | -59.12% | ― | ― | -12.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr31.42M | -0.38 | -151.94% | ― | ― | 57.42% | |
42 Neutral | kr602.98M | -1.68 | ― | ― | 109.22% | 27.30% | |
41 Neutral | kr71.17M | -0.90 | -72.62% | ― | ― | 51.40% |
* Healthcare Sector Average
SE:SYNACT
SynAct Pharma AB
18.26
-1.84
-9.15%
SE:ONCO
Oncopeptides AB
1.58
-3.44
-68.52%
SE:SANION
Saniona AB
14.23
5.24
58.29%
SE:ACE
Ascelia Pharma AB
0.53
-4.23
-88.81%
SE:GUARD
Guard Therapeutics International AB
1.56
-18.24
-92.13%
SE:CANTA
Cantargia AB
1.82
-1.33
-42.25%
SynAct Pharma AB Corporate Events
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
Jul 20, 2026
SynAct Pharma has secured access to a new strategic financing facility of up to SEK 100 million and has initially drawn SEK 50 million through the issuance of convertible loans. The move strengthens the biotech’s balance sheet, broadens its ...
SynAct preclinical data point to osteoarthritis potential for resomelagon
Jul 9, 2026
SynAct Pharma AB reported early preclinical data indicating that its drug candidate resomelagon (AP1189) can reduce inflammation, joint damage and pain in a mouse model of osteoarthritis, a condition affecting hundreds of millions globally. The fi...
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
Jun 29, 2026
SynAct Pharma reported a marked increase in interest from pharmaceutical companies and specialized healthcare investors after presenting positive ADVANCE study results for its lead candidate resomelagon at the BIO International Convention in San D...
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
Jun 15, 2026
SynAct Pharma’s entire shareholding board and management team have entered into lock-up agreements, pledging not to sell or otherwise dispose of their shares and related securities until the end of 2026. The move is presented as a strong sig...
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
Jun 15, 2026
SynAct Pharma reported Phase 2b ADVANCE trial data showing that its oral candidate resomelagon, added to methotrexate, produced strong clinical responses and biomarker improvements in newly diagnosed, highly active rheumatoid arthritis patients, w...
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
Jun 12, 2026
SynAct Pharma AB has secured a key U.S. patent for its lead candidate resomelagon (AP1189), which will now run until July 2044 after a Patent Term Adjustment of 742 days. The patent underpins the company’s strategy around developing resomela...
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
Jun 11, 2026
SynAct Pharma AB’s 2026 Annual General Meeting approved the 2025 financial statements, confirmed that no dividend will be paid with profits carried forward, and granted discharge from liability to the board and CEO, underscoring a capital-pr...
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
May 27, 2026
SynAct Pharma has released its interim report for the first quarter of 2026, outlining significant events in the period, financial development, and ongoing research and development activities in inflammatory diseases. The report highlights managem...
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
May 26, 2026
SynAct Pharma AB reported that it had been notified by a large shareholder about a market order to sell up to roughly one million shares placed on May 25, which stemmed from an operational error between the shareholder and its bank. According to t...
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
May 19, 2026
SynAct Pharma will present at the BioStock Global Forum 2026 in Lund, using the investor-focused event to highlight its lead candidate resomelagon and attract strategic partners. The company plans to update attendees on the latest developments aro...
SynAct Pharma convenes AGM and opts to retain earnings
May 7, 2026
SynAct Pharma AB has called its annual general meeting for 11 June 2026 in Stockholm, inviting shareholders to participate in person or by proxy subject to registration with Euroclear Sweden and timely notification to the company. The agenda cover...
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
May 6, 2026
SynAct Pharma has completed dosing of the last patient in its Phase 2b ADVANCE study of resomelagon in newly diagnosed rheumatoid arthritis patients starting first-line methotrexate therapy. The trial, conducted at more than 30 sites and involving...
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
May 5, 2026
SynAct Pharma plans to use its presence at the LSX Nordic Congress in Copenhagen on May 19-20, 2026 to engage with investors and potential pharmaceutical partners as it advances its inflammation-focused pipeline. Senior executives, including the C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.